A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases.
ARDS
Bradykinin storm
Inflammation
Kinin receptors
RAAS pathway
Vasodilator
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
16
12
2021
accepted:
28
04
2022
pubmed:
21
5
2022
medline:
30
9
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
Bradykinin, a member of the kallikrein-kinin system (KKS), is a potent, short-lived vasoactive peptide that acts as a vasodilator and an inflammatory mediator in a number of signaling mechanisms. Bradykinin induced signaling is mediated through kinin B1 (BDKRB1) and B2 (BDKRB2) transmembrane receptors coupled with different subunits of G proteins (G
Identifiants
pubmed: 35596055
doi: 10.1007/s11033-022-07539-2
pii: 10.1007/s11033-022-07539-2
pmc: PMC9122735
doi:
Substances chimiques
Interleukin-2
0
Interleukin-6
0
Interleukin-8
0
Receptors, Bradykinin
0
Vasodilator Agents
0
Bradykinin
S8TIM42R2W
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9915-9927Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Costa-Neto CM et al (2008) Participation of kallikrein-kinin system in different pathologies. Int Immunopharmacol 8(2):135–142
pubmed: 18182216
doi: 10.1016/j.intimp.2007.08.003
Mombouli JV, Vanhoutte PM (1995) Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35:679–705
pubmed: 7598512
doi: 10.1146/annurev.pa.35.040195.003335
Sharma JN (2014) Basic and clinical aspects of bradykinin receptor antagonists. Prog Drug Res 69:1–14
pubmed: 25130037
Rodell TC (1996) The kallikrein/kinin system and kinin antagonists in trauma. Immunopharmacology 33(1–3):279–283
pubmed: 8856162
doi: 10.1016/0162-3109(96)00071-9
Dagnino APA, Campos MM, Silva RBM (2020) Kinins and their receptors in infectious diseases. Pharmaceuticals (Basel) 13(9):215
doi: 10.3390/ph13090215
Lau J et al (2020) A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors. Pharmaceuticals (Basel) 13(8):199
doi: 10.3390/ph13080199
Wang S et al (2008) Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. Brain 131(Pt 5):1241–1251
pubmed: 18356188
doi: 10.1093/brain/awn060
Couture R et al (2001) Kinin receptors in pain and inflammation. Eur J Pharmacol 429(1–3):161–176
pubmed: 11698039
doi: 10.1016/S0014-2999(01)01318-8
Rex DAB et al (2022) A modular map of Bradykinin-mediated inflammatory signaling network. J Cell Commun Signal 16(2):301–310
pubmed: 34714516
doi: 10.1007/s12079-021-00652-0
Garvin MR et al (2020) A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. https://doi.org/10.7554/eLife.59177
doi: 10.7554/eLife.59177
pubmed: 32633718
pmcid: 7410499
Marceau F et al (2020) Bradykinin receptors: agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. Int Immunopharmacol 82:106305
pubmed: 32106060
doi: 10.1016/j.intimp.2020.106305
Kashuba E et al (2013) The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers 18(4):279–296
pubmed: 23672534
doi: 10.3109/1354750X.2013.787544
Leeb-Lundberg LM et al (2005) International union of pharmacology XLV Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57(1):27–77
pubmed: 15734727
doi: 10.1124/pr.57.1.2
Stewart JM et al (2002) Bradykinin-related compounds as new drugs for cancer and inflammation. Can J Physiol Pharmacol 80(4):275–280
pubmed: 12025961
doi: 10.1139/y02-030
Kitamura N et al (1985) Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 260(14):8610–8617
pubmed: 2989294
doi: 10.1016/S0021-9258(17)39516-9
Linz W et al (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47(1):25–49
pubmed: 7784479
From the American Association of Neurological Surgeons, ASoNC, et al., Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke, 2018. 13(6): 612–632.
Bryant JW, Shariat-Madar Z (2009) Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem 7(3):234–250
pubmed: 19689262
pmcid: 4905712
doi: 10.2174/187152509789105444
Bjorkqvist J, Jamsa A, Renne T (2013) Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 110(3):399–407
pubmed: 23846131
doi: 10.1160/TH13-03-0258
Pathak M et al (2013) Structure of plasma and tissue kallikreins. Thromb Haemost 110(3):423–433
pubmed: 23494059
doi: 10.1160/TH12-11-0840
Clements J, Mukhtar A (1997) Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology 36(2–3):217–220
pubmed: 9228549
doi: 10.1016/S0162-3109(97)00024-6
Boyukozer FB et al (2020) Kallikrein gene family as biomarkers for recurrent prostate cancer. Croat Med J 61(5):450–456
pubmed: 33150763
doi: 10.3325/cmj.2020.61.450
Nokkari A et al (2018) Implication of the Kallikrein-Kinin system in neurological disorders: quest for potential biomarkers and mechanisms. Prog Neurobiol 165–167:26–50
pubmed: 29355711
pmcid: 6026079
doi: 10.1016/j.pneurobio.2018.01.003
Golias C et al (2007) The kinin system–bradykinin biological effects and clinical implications. Multiple role of the kinin system–bradykinin. Hippokratia 11(3):124–128
pubmed: 19582206
pmcid: 2658795
Hopsu-Havu VK, Makinen KK, Glenner GG (1966) Formation of bradykinin from kallidin-10 by aminopeptidase B. Nature 212(5067):1271–1272
pubmed: 21090475
doi: 10.1038/2121271a0
Zhang X et al (2011) Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J Biol Chem 286(21):18547–18561
pubmed: 21454694
pmcid: 3099671
doi: 10.1074/jbc.M110.214940
Scholzen TE, Luger TA (2004) Neutral endopeptidase and angiotensin-converting enzyme—key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol 13(Suppl 4):22–26
pubmed: 15507108
doi: 10.1111/j.1600-0625.2004.00260.x
Rex DAB et al (2021) Broadening COVID-19 Interventions to Drug innovation: neprilysin pathway as a friend, foe, or promising molecular target? OMICS 25(7):408–416
pubmed: 34191617
doi: 10.1089/omi.2021.0080
Kayashima K, Ueki M, Kinoshita Y (2012) Ultrasonic analysis of the anatomical relationships between vertebral arteries and internal jugular veins in children. Paediatr Anaesth 22(9):854–858
pubmed: 22340889
pmcid: 3469738
doi: 10.1111/j.1460-9592.2012.03816.x
Regoli DC, Marceau F, Lavigne J (1981) Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. Eur J Pharmacol 71(1):105–115
pubmed: 6113153
doi: 10.1016/0014-2999(81)90391-5
Hess JF et al (1992) Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 184(1):260–268
pubmed: 1314587
doi: 10.1016/0006-291X(92)91187-U
Shughrue PJ, Ky B, Austin CP (2003) Localization of B1 bradykinin receptor mRNA in the primate brain and spinal cord: an in situ hybridization study. J Comp Neurol 465(3):372–384
pubmed: 12966562
doi: 10.1002/cne.10846
Raidoo DM, Bhoola KD (1997) Kinin receptors on human neurones. J Neuroimmunol 77(1):39–44
pubmed: 9209266
doi: 10.1016/S0165-5728(97)00048-9
Marceau F et al (1983) Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol 14(2):209–229
pubmed: 6132853
doi: 10.1016/0306-3623(83)90001-0
Ghebrehiwet B et al (2014) Soluble gC1qR is an autocrine signal that induces B1R expression on endothelial cells. J Immunol 192(1):377–384
pubmed: 24319267
doi: 10.4049/jimmunol.1302031
Koumbadinga GA et al (2010) Effect of interferon-gamma on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells. Eur J Pharmacol 647(1–3):117–125
pubmed: 20813106
doi: 10.1016/j.ejphar.2010.08.008
Marceau F, Bachvarov DR (1998) Kinin receptors. Clin Rev Allergy Immunol 16(4):385–401
pubmed: 9926287
doi: 10.1007/BF02737658
Zhang X, Tan F, Skidgel RA (2013) Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor. J Biol Chem 288(46):33226–33240
pubmed: 24108126
pmcid: 3829169
doi: 10.1074/jbc.M113.520791
Wu J et al (2002) Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 98(1):29–35
pubmed: 11857381
doi: 10.1002/ijc.10142
Bockmann S, Paegelow I (2000) Kinins and kinin receptors: importance for the activation of leukocytes. J Leukoc Biol 68(5):587–592
pubmed: 11073095
doi: 10.1189/jlb.68.5.587
Walker K, Perkins M, Dray A (1995) Kinins and kinin receptors in the nervous system. Neurochem Int 26(1):1–16
pubmed: 7787759
doi: 10.1016/0197-0186(94)00114-A
Blaukat A et al (2001) Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function. J Biol Chem 276(44):40431–40440
pubmed: 11517230
doi: 10.1074/jbc.M107024200
Pizard A et al (1999) Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 274(18):12738–12747
pubmed: 10212257
doi: 10.1074/jbc.274.18.12738
Enquist J et al (2007) Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis. Mol Pharmacol 71(2):494–507
pubmed: 17110500
doi: 10.1124/mol.106.030858
Fortin JP, Bouthillier J, Marceau F (2003) High agonist-independent clearance of rabbit kinin B1 receptors in cultured cells. Am J Physiol Heart Circ Physiol 284(5):H1647–H1654
pubmed: 12521931
doi: 10.1152/ajpheart.00884.2002
Brusco I et al (2021) Inhibitors of angiotensin I converting enzyme potentiate fibromyalgia-like pain symptoms via kinin receptors in mice. Eur J Pharmacol 895:173870
pubmed: 33476653
doi: 10.1016/j.ejphar.2021.173870
Goncalves ECD et al (2021) Bradykinin receptors play a critical role in the chronic post-ischaemia pain model. Cell Mol Neurobiol 41(1):63–78
pubmed: 32222846
doi: 10.1007/s10571-020-00832-3
Falsetta ML et al (2016) A Role for bradykinin signaling in chronic vulvar pain. J Pain 17(11):1183–1197
pubmed: 27544818
pmcid: 6226004
doi: 10.1016/j.jpain.2016.07.007
Naffah-Mazzacoratti Mda G et al (2014) What have we learned about the kallikrein-kinin and renin-angiotensin systems in neurological disorders? World J Biol Chem 5(2):130–140
pubmed: 24921004
Bossi F et al (2009) Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 124(6):1303–1310
pubmed: 19796797
pmcid: 2798851
doi: 10.1016/j.jaci.2009.08.007
Tschope C, Schultheiss HP, Walther T (2002) Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol 39(4):478–487
pubmed: 11904521
doi: 10.1097/00005344-200204000-00003
Albert-Weissenberger C, Siren AL, Kleinschnitz C (2013) Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system. Prog Neurobiol 101–102:65–82
pubmed: 23274649
doi: 10.1016/j.pneurobio.2012.11.004
Kayashima Y, Smithies O, Kakoki M (2012) The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens 21(1):92–96
pubmed: 22048723
pmcid: 3657726
doi: 10.1097/MNH.0b013e32834d54b1
Kakoki M, Smithies O (2009) The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 75(10):1019–1030
pubmed: 19190676
pmcid: 3733452
doi: 10.1038/ki.2008.647
Kaplan AP, Ghebrehiwet B (2021) Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. J Allergy Clin Immunol 147(2):507–509
pubmed: 33129885
doi: 10.1016/j.jaci.2020.10.025
Oschatz C et al (2011) Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34(2):258–268
pubmed: 21349432
doi: 10.1016/j.immuni.2011.02.008
Brunnee T et al (1997) Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 27(6):653–663
pubmed: 9208186
doi: 10.1111/j.1365-2222.1997.tb01193.x
Motta Junior JDS et al (2020) Mast cells in alveolar septa of COVID-19 patients a pathogenic pathway that may link interstitial edema to immunothrombosis. Front Immunol 11:574862
pubmed: 33042157
pmcid: 7530169
doi: 10.3389/fimmu.2020.574862
van de Veerdonk FL et al (2020) Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. https://doi.org/10.7554/eLife.57555
doi: 10.7554/eLife.57555
pubmed: 32338605
pmcid: 7213974
Sodhi CP et al (2018) Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol 314(1):L17–L31
pubmed: 28935640
doi: 10.1152/ajplung.00498.2016
Hoffmann M et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Xu X et al (2020) Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 63(3):457–460
pubmed: 32009228
pmcid: 7089049
doi: 10.1007/s11427-020-1637-5
Vickers C et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277(17):14838–14843
pubmed: 11815627
doi: 10.1074/jbc.M200581200
Dicpinigaitis PV (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 129(1 Suppl):169S-173S
pubmed: 16428706
doi: 10.1378/chest.129.1_suppl.169S
Meini S et al (2020) Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life. Eur Arch Otorhinolaryngol 277(12):3519–3523
pubmed: 32500326
pmcid: 7271634
doi: 10.1007/s00405-020-06102-8
Scangas GA, Bleier BS (2017) Anosmia: Differential diagnosis, evaluation, and management. Am J Rhinol Allergy 31(1):3–7
pubmed: 28234141
doi: 10.2500/ajra.2017.31.4403
Zhu L et al (2010) Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 56(3):384–390
pubmed: 20606103
doi: 10.1161/HYPERTENSIONAHA.110.155051
Ruocco G, Feola M, Palazzuoli A (2020) Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. Int J Infect Dis 95:373–375
pubmed: 32335337
pmcid: 7180155
doi: 10.1016/j.ijid.2020.04.058
Jamilloux Y et al (2020) Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 19(7):102567
pubmed: 32376392
pmcid: 7196557
doi: 10.1016/j.autrev.2020.102567
Liu Y et al (2020) Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 63(3):364–374
pubmed: 32048163
pmcid: 7088566
doi: 10.1007/s11427-020-1643-8
Spagnolo P et al (2020) Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med 8(8):750–752
pubmed: 32422177
pmcid: 7228737
doi: 10.1016/S2213-2600(20)30222-8
Frater JL et al (2020) COVID-19 and the clinical hematology laboratory. Int J Lab Hematol 42(Suppl 1):11–18
pubmed: 32311826
pmcid: 7264622
doi: 10.1111/ijlh.13229
Thachil J (2020) The versatile heparin in COVID-19. J Thromb Haemost 18(5):1020–1022
pubmed: 32239799
doi: 10.1111/jth.14821
Lillicrap D (2020) Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost 18(4):786–787
pubmed: 32212240
pmcid: 7166410
doi: 10.1111/jth.14781
Gattinoni L, Chiumello D, Rossi S (2020) COVID-19 pneumonia: ARDS or not? Crit Care 24(1):154
pubmed: 32299472
pmcid: 7160817
doi: 10.1186/s13054-020-02880-z
Green SJ (2020) Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect 22(4–5):149–150
pubmed: 32425647
pmcid: 7229726
doi: 10.1016/j.micinf.2020.05.006
Varga Z et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418
pubmed: 32325026
pmcid: 7172722
doi: 10.1016/S0140-6736(20)30937-5
Desmazes C, Gauthier F, Lalmanach G (2001) Cathepsin L, but not cathepsin B, is a potential kininogenase. Biol Chem 382(5):811–815
pubmed: 11517935
doi: 10.1515/bchm.2001.382.5.811
Desmazes C et al (2003) Kininogen-derived peptides for investigating the putative vasoactive properties of human cathepsins K and L. Eur J Biochem 270(1):171–178
pubmed: 12492488
doi: 10.1046/j.1432-1033.2003.03382.x
Puzer L et al (2005) A possible alternative mechanism of kinin generation in vivo by cathepsin L. Biol Chem 386(7):699–704
pubmed: 16207091
doi: 10.1515/BC.2005.081
Cure E, Cumhur Cure M, Vatansev H (2020) Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension. J Renin Angiotensin Aldosterone Syst 21(4):14703203
doi: 10.1177/1470320320972015
Fan E, Brodie D, Slutsky AS (2018) Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA 319(7):698–710
pubmed: 29466596
doi: 10.1001/jama.2017.21907
Krankel N et al (2008) Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res 103(11):1335–1343
pubmed: 18927465
pmcid: 2821015
doi: 10.1161/CIRCRESAHA.108.179952
Chao J et al (2007) Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen-activated protein kinase activity. Hypertension 49(3):490–497
pubmed: 17224475
doi: 10.1161/01.HYP.0000255925.01707.eb
Gross GJ et al (2011) Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome P450 epoxygenase pathway in canine hearts. Cardiovasc Drugs Ther 25(6):517–522
pubmed: 21786213
pmcid: 3329256
doi: 10.1007/s10557-011-6321-9
Penna C et al (2007) Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res 75(1):168–177
pubmed: 17400201
doi: 10.1016/j.cardiores.2007.03.001
Yin H et al (2007) Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 28(7):1383–1389
pubmed: 17644219
pmcid: 2067250
doi: 10.1016/j.peptides.2007.05.010
Feng J et al (2005) Bradykinin preconditioning improves the profile of cell survival proteins and limits apoptosis after cardioplegic arrest. Circulation 112(9 Suppl):I190–I195
pubmed: 16159814
Potier L et al (2013) Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J Pharmacol Exp Ther 346(1):23–30
pubmed: 23591995
doi: 10.1124/jpet.113.203927
Blaes N, Girolami JP (2013) Targeting the “Janus face” of the B2-bradykinin receptor. Expert Opin Ther Targets 17(10):1145–1166
pubmed: 23957374
doi: 10.1517/14728222.2013.827664
Yao YY et al (2007) Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail 13(7):588–596
pubmed: 17826650
pmcid: 4519013
doi: 10.1016/j.cardfail.2007.04.009
Wei CC et al (2012) Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS ONE 7(6):e40110
pubmed: 22768235
pmcid: 3387019
doi: 10.1371/journal.pone.0040110
Petho G, Reeh PW (2012) Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. Physiol Rev 92(4):1699–1775
pubmed: 23073630
doi: 10.1152/physrev.00048.2010
Qin C et al (2009) Bradykinin is involved in the mediation of cardiac nociception during ischemia through upper thoracic spinal neurons. Curr Neurovasc Res 6(2):89–94
pubmed: 19442157
doi: 10.2174/156720209788185623
Offermanns S (2006) Activation of platelet function through G protein-coupled receptors. Circ Res 99(12):1293–1304
pubmed: 17158345
doi: 10.1161/01.RES.0000251742.71301.16
Birbrair A et al (2014) Type-1 pericytes accumulate after tissue injury and produce collagen in an organ-dependent manner. Stem Cell Res Ther 5(6):122
pubmed: 25376879
pmcid: 4445991
doi: 10.1186/scrt512
Wynn TA (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4(8):583–594
pubmed: 15286725
pmcid: 2702150
doi: 10.1038/nri1412
Schanstra JP et al (2002) In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110(3):371–379
pubmed: 12163456
pmcid: 151090
doi: 10.1172/JCI0215493
Kakoki M et al (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 104(18):7576–7581
pubmed: 17452647
pmcid: 1855073
doi: 10.1073/pnas.0701617104
Zhang JJ et al (2004) Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66(2):722–732
pubmed: 15253727
doi: 10.1111/j.1523-1755.2004.00794.x
Madeddu P et al (2000) Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice. Hypertension 35(1 Pt 2):391–396
pubmed: 10642330
doi: 10.1161/01.HYP.35.1.391
Takemoto M et al (1997) Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30(6):1621–1627
pubmed: 9403592
doi: 10.1161/01.HYP.30.6.1621
Veeravalli KK, Akula A (2004) Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction. Pharmacol Res 49(1):23–29
pubmed: 14597148
doi: 10.1016/j.phrs.2003.07.010
Yin H, Chao L, Chao J (2005) Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14–3–3 signaling pathways. J Biol Chem 280(9):8022–8030
pubmed: 15611141
doi: 10.1074/jbc.M407179200
Xie P et al (2000) Activation of NF-kappa B by bradykinin through a Galpha(q)- and Gbeta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. J Biol Chem 275(32):24907–24914
pubmed: 10801799
doi: 10.1074/jbc.M001051200
Lesage A et al (2020) In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist. Front Pharmacol 11:916
pubmed: 32636746
pmcid: 7316994
doi: 10.3389/fphar.2020.00916
Campos MM et al (2006) Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol Sci 27(12):646–651
pubmed: 17056130
doi: 10.1016/j.tips.2006.10.007
Marceau F, Regoli D (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3(10):845–852
pubmed: 15459675
doi: 10.1038/nrd1522
Rhaleb NE et al (1991) Structure-activity studies of bradykinin and related peptides B2-receptor antagonists. Hypertension 17(1):107–115
pubmed: 1846119
doi: 10.1161/01.HYP.17.1.107
Vavrek RJ, Stewart JM (1985) Competitive antagonists of bradykinin. Peptides 6(2):161–164
pubmed: 4034408
doi: 10.1016/0196-9781(85)90033-6
Wirth K et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102(3):774–777
pubmed: 1364852
pmcid: 1917928
doi: 10.1111/j.1476-5381.1991.tb12249.x
Regoli D et al (1990) Kinin receptor subtypes. J Cardiovasc Pharmacol 15(Suppl 6):S30–S38
pubmed: 1697358
doi: 10.1097/00005344-199015061-00007
Whalley ET et al (2012) Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov 7(12):1129–1148
pubmed: 23095011
doi: 10.1517/17460441.2012.729038
Hock FJ et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102(3):769–773
pubmed: 1364851
pmcid: 1917958
doi: 10.1111/j.1476-5381.1991.tb12248.x
Gobeil F, Regoli D (1994) Characterization of kinin receptors by bioassays. Braz J Med Biol Res 27(8):1781–1791
pubmed: 7749368
Lembeck F et al (1991) New, long-acting, potent bradykinin antagonists. Br J Pharmacol 102(2):297–304
pubmed: 2015416
pmcid: 1918044
doi: 10.1111/j.1476-5381.1991.tb12169.x
Akbary AM, Wirth KJ, Scholkens BA (1996) Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology 33(1–3):238–242
pubmed: 8856156
doi: 10.1016/0162-3109(96)00065-3
Austin CE, Foreman JC, Scadding GK (1994) Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. Br J Pharmacol 111(4):969–971
pubmed: 8032622
pmcid: 1910147
doi: 10.1111/j.1476-5381.1994.tb14835.x
Dray A, Perkins M (1993) Bradykinin and inflammatory pain. Trends Neurosci 16(3):99–104
pubmed: 7681240
doi: 10.1016/0166-2236(93)90133-7
McNeil BD et al (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519(7542):237–241
pubmed: 25517090
doi: 10.1038/nature14022
Cicardi M et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363(6):532–541
pubmed: 20818888
pmcid: 4662377
doi: 10.1056/NEJMoa0906393
Cheronis JC et al (1992) A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem 35(9):1563–1572
pubmed: 1578482
doi: 10.1021/jm00087a010
Gessi S et al (1997) Human vascular kinin receptors of the B2 type characterized by radioligand binding. Br J Pharmacol 122(7):1450–1454
pubmed: 9421294
pmcid: 1565092
doi: 10.1038/sj.bjp.0701536
Scherrer D et al (1995) Effects of WIN 64338, a nonpeptide bradykinin B2 receptor antagonist, on guinea-pig trachea. Br J Pharmacol 115(7):1127–1128
pubmed: 7582533
pmcid: 1908803
doi: 10.1111/j.1476-5381.1995.tb15013.x
Farmer SG, DeSiato MA (1994) Effects of a novel nonpeptide bradykinin B2 receptor antagonist on intestinal and airway smooth muscle: further evidence for the tracheal B3 receptor. Br J Pharmacol 112(2):461–464
pubmed: 8075864
pmcid: 1910382
doi: 10.1111/j.1476-5381.1994.tb13095.x
Inamura N et al (1997) Characterization of FR173657, a novel nonpeptide B2 antagonist: in vitro and in vivo studies. Can J Physiol Pharmacol 75(6):622–628
pubmed: 9276139
doi: 10.1139/y97-021
Aramori I et al (1997) Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol Pharmacol 51(2):171–176
pubmed: 9203620
doi: 10.1124/mol.51.2.171
Simmon VF (2009) Response to The BRAIN TRIAL a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 10:110
pubmed: 19958522
pmcid: 2797007
doi: 10.1186/1745-6215-10-110
Shakur H et al (2009) The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 10:109
pubmed: 19958521
pmcid: 2794266
doi: 10.1186/1745-6215-10-109
Pruneau D et al (1999) Pharmacological profile of LF 16–0687, a new potent non-peptide bradykinin B2 receptor antagonist. Immunopharmacology 43(2–3):187–194
pubmed: 10596852
doi: 10.1016/S0162-3109(99)00128-9
Gomis A et al (2013) Blockade of nociceptive sensory afferent activity of the rat knee joint by the bradykinin B2 receptor antagonist fasitibant. Osteoarthritis Cartilage 21(9):1346–1354
pubmed: 23973149
doi: 10.1016/j.joca.2013.03.013
Valenti C et al (2005) MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. J Pharmacol Exp Ther 315(2):616–623
pubmed: 16027229
doi: 10.1124/jpet.105.088252
Kenniston JA et al (2014) Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem 289(34):23596–23608
pubmed: 24970892
pmcid: 4156074
doi: 10.1074/jbc.M114.569061
Wu MA (2019) Lanadelumab for the treatment of hereditary angioedema. Expert Opin Biol Ther 19(12):1233–1245
pubmed: 31657963
doi: 10.1080/14712598.2019.1685490
Kaplon H, Reichert JM (2019) Antibodies to watch in 2019. MAbs 11(2):219–238
pubmed: 30516432
doi: 10.1080/19420862.2018.1556465
Balaguer JM et al (2013) Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial. Clin Pharmacol Ther 93(4):326–334
pubmed: 23361105
doi: 10.1038/clpt.2012.249
Charignon D et al (2012) Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother 13(15):2233–2247
pubmed: 22970904
doi: 10.1517/14656566.2012.723692
Marmarou A et al (1999) Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. American Brain Injury Consortium Study Group. J Neurotrauma 16(6):431–444
pubmed: 10391361
doi: 10.1089/neu.1999.16.431
Narotam PK et al (1998) Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir (Wien) 140(8):793–802
doi: 10.1007/s007010050181
Fein AM et al (1997) Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial CP-0127 SIRS and Sepsis Study Group. JAMA 277(6):482–487
pubmed: 9020273
doi: 10.1001/jama.1997.03540300050033
Lesage A et al (2022) In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B2 receptor antagonist in clinical development. Int Immunopharmacol 105:108523
pubmed: 35086057
doi: 10.1016/j.intimp.2022.108523